Medovir (Aciclovir)

Aciclovir is taken up by virus‑infected cells and phosphorylated by viral thymidine kinase to its monophosphate form, then to the active triphosphate. This triphosphate competitively inhibits viral DNA polymerase, causing premature termination of viral DNA synthesis while sparing host cellular DNA.

The dosage of Medovir is determined by the prescribing clinician based on the specific indication, patient age, renal function, and severity of infection. The prescriber selects the appropriate strength and regimen for each individual case.

Safety data for aciclovir during pregnancy are limited, and it is classified as a pregnancy category unknown. Use is only recommended when the potential benefit justifies any potential risk. Small amounts are excreted in breast milk, so breastfeeding mothers should discuss use with a healthcare professional.

To order Medovir, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The main alternative is valacyclovir, a pro‑drug of aciclovir. Medovir delivers the active molecule directly, offering comparable antiviral efficacy but often requires more frequent dosing. Valacyclovir provides higher oral bioavailability, allowing less frequent dosing, while both share similar safety profiles.

Medovir tablets should be stored at ambient temperature, below 25 °C, in the original container to protect from moisture and light. Keep the product out of reach of children and do not use after the expiry date indicated on the packaging.

Medovir is taken orally, usually with a full glass of water. It may be taken with or without food, but consistent timing relative to meals can help maintain stable drug levels. Patients should follow the prescriber’s instructions regarding dosing frequency and duration of therapy.

The most serious risks include renal toxicity, especially in patients with pre‑existing kidney disease, and rare severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. Neurological events like seizures may also occur at high plasma concentrations.

Medovir is contraindicated in individuals with known hypersensitivity to aciclovir or any excipients in the formulation. Caution is advised for patients with severe renal impairment, and it should be avoided when the risk of serious adverse reactions outweighs the therapeutic benefit.